AzurRx BioPharma

From Verify.Wiki
Jump to: navigation, search
Azb.jpg
http://www.azurrx.com/
AzurRx BioPharma
Type Public
Industry Pharmaceutical
Founded 2014
Headquarters Brooklyn, NY
Key people Thijs Spoor(President), Daniel Dupret(Chief Scientific Officer), George Harb(MD)[1]
Investors WallachBeth Capital and Network 1 Financial Securities[2][3]
Number of employees 12 [4]

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders[5]. Its product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase for exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant ß-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. The company was incorporated in 2014 and is based in Brooklyn, New York.AzurRx BioPharma is developing a treatment for pancreatic insufficiency with the scientific backing of European biopharma researchers, it has earned Phase 1 clinical trial success for its lead candidate.[6]

History

  • July 31, 2014, AzurRx announces issuance of U.S. Patent for its MS1819 lipase compound.[7]
  • May 28, 2015, AzurRx announces addition of Ed Borkowski to the Board of Directors.[8]
  • January 11, 2016, AzurRx President Thijs Spoor made a presentation at the 8th Annual Biotech Showcase 2016 meeting in San Francisco.[9]
  • AzurRX and Protea Biosciences Group, Inc. and its wholly owned subsidiary Protea Biosciences, Inc. entered into a stock purchase and sale agreement with AzurRx BioPharma, Inc.[10][11]
  • October 12, 2016, AzurRx BioPharma Inc. announced that its initial public offering of 960,000 shares of common stock has been priced at $5.50 per share.[12][13]
  • October 12, 2016, AzurRX had to dip under its lowest range of $6 to $8 to just $5.50, raising $5 million through just under 1 million shares.[14]
  • October 19, 2016, AzurRx BioPharma Inc. to ring the Nasdaq stock market Closing Bell.[15]

Controversies

Top 5 Recent Tweets

DateAuthorComment
December 13, 2018marketexclusive$AZRX AZURRX BIOPHARMA, INC. (NASDAQ:AZRX) Files An 8-K Entry into a Material Definitive Agreement https://t.co/FoSEGjaPiy
December 13, 2018AmericanBankingAzurRx BioPharma $AZRX Given a $8.00 Price Target by HC Wainwright Analysts https://t.co/9f9R0P5Res #stocks
December 13, 2018bwcan82AzurRx BioPharma (AZRX) Given a $8.00 Price Target by HC Wainwright Analysts https://t.co/Sf2mHzFFW5 via @RatingsNetwork
December 13, 2018ZolmaxNewsAzurRx BioPharma $AZRX Given a $8.00 Price Target by HC Wainwright Analysts https://t.co/qlGvF3SCEj


Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines

  1. http://www.azurrx.com/about-us/leadership
  2. https://www.crunchbase.com/funding-round/555754fb5508350e23191f3b311d3195
  3. http://www.xdata.co/story.php?a=000141588916005478&c=1604191
  4. http://www.nasdaq.com/markets/ipos/company/azurrx-biopharma-inc-931278-81303
  5. http://www.gastrojournal.org/article/S0016-5085(15)01524-3/fulltext
  6. https://www.ncbi.nlm.nih.gov/pubmed/26327131
  7. http://www.azurrx.com/news-events/press-releases/2014/58-http-www-azurrx-com-administrator-index-php-option-com-content-view-article-layout-edit
  8. http://www.azurrx.com/news-events/press-releases/2015/60-azurrx-announces-addition-of-ed-borkowski-to-the-board-of-directors
  9. http://www.azurrx.com/news-events/events
  10. https://ipscio.com/licensing-economics-review/protea-azurrx-and-mayoly-spindler-in-may-protea-biosciences-group-inc/
  11. http://www.loeb.com/experience-proteabioeuropecapitalstockacquisition
  12. http://www.businesswire.com/news/home/20161012005235/en/AzurRx-BioPharma-Announces-Pricing-Initial-Public-Offering
  13. http://seekingalpha.com/article/4000740-azurrx-biopharma-ultra-high-risk-ipo
  14. http://www.fiercebiotech.com/biotech/azurrx-biopharma-discounts-5m-ipo-as-accelerated-pharma-files-for-19m-offering
  15. http://www.azurrx.com/news-events/press-releases/2016/75-azurrx-biopharma-inc-nasdaq-azrx-to-ring-the-nasdaq-stock-market-closing-bell

Verification history